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Lithium triborate laser vaporization of the prostate using the 120
w, high performance system laser: high performance all the way?
Abstract
Despite technical refinements of the 120 W lithium-triborate laser fiber degradation and significantly
decreased power output are still detectable during the procedure. Laser fibers are not fully appropriate
for the high power delivery of the new system. There is still potential for further improvement in the
laser performance.
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Abstract 
Purpose: The technical modifications of the 120W lithium-triborate (LBO) laser have been 
implemented to increase the power output and to prevent laser fibre degradation and loss of 
power output during laser vaporisation (LV) of the prostate. However, visible alterations at 
the fibre-tip and the subjective impression of a decreasing ablative effectiveness during LBO-
LV indicate that the delivery of a constantly high laser power remains a relevant problem. 
Therefore, the extent to which laser fibre degradation and loss of power output take place 
during 120W LBO-LV of the prostate was evaluated. 
Material and Methods: Forty-six laser fibres were investigated during routine 120W LBO-
LV in 35 patients suffering from prostatic bladder outflow obstruction. Laser beam power was 
measured at baseline and after the application of every 25kJ during LV. The fibre-tips were 
microscopically examined after the procedure. 
Results: Mild to moderate degradation at the emission window associated with a loss of 
power output occurred in all fibres. A steep decrease to a median power output of 57.3% of 
the baseline value was detectable after the application of the first 25kJ. The median power 
output at the end of the defined 275kJ-lifespan of the fibres was 48.8%.  
Conclusions: Despite the technical refinements of the 120W LBO-laser, fibre degradation 
and a significant decrease of power output are still detectable during the procedure. The laser 
fibres are not fully appropriate for the high power delivery of the new system. Thus, there is 
still potential for further improvement of the laser’s performance. 
 
 
 
 
 
 
 3
Introduction 
Since its clinical introduction for prostatic de-obstruction in 1998, the 532nm greenlight laser 
system has experienced numerous modifications in order to optimize its performance.1-3 The 
early low-powered 60W potassium-titanyl-phosphate (KTP) laser system was soon to be 
replaced by the more potent 80W system, which found a wide acceptance in urological 
practice at the beginning of this century.2,4-7  
Despite excellent clinical short- to mid-term results8-12 several weak points of the procedure 
have also been identified.13-15 Prolonged irritative voiding symptoms and post-operative 
urinary retention have been described as typical side effects of KTP-laser vaporisation 
(LV).9,15 Laser fibre degradation leading to a significant loss of power output during the 
operation has been identified as one possible reason for post-operative voiding problems.13 
The reduced power output results in inefficient tissue ablation and increased tissue 
coagulation.16,17 The latter is known to cause post-operative irritative voiding symptoms, 
whereas insufficient tissue ablation might impair the long-term efficacy of the procedure.18,19 
The typical problems of the KTP-laser called for further technical refinements. In 2006 the 
120W high performance system (HPS) lithium triborate (LBO) laser has been introduced. 
Higher power and modifications of the laser beam leading to a faster and more efficient non-
contact vaporisation have been reported.3 Surgically, an improved performance was clearly 
evident. However, macroscopic alterations of the fibre-tip and a decreasing ablative efficiency 
during the procedure again became apparent. The objective of the present investigation was to 
evaluate the performance of the HPS system with regard to structural changes of the laser 
fibre and associated changes in power output during treatment.  
 
Material and Methods 
LBO-LV was performed using the 120W GreenLight HPS™ laser (AMS®, Minnetonka, MN, 
USA). Between July 2008 and August 2009, 46 IQ™ Greenlight HPS® bPH fibres (AMS®) 
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were investigated during routine LBO-LV in 35 patients suffering from prostatic bladder 
outflow obstruction. Patient characteristics are summarised in table 1. Two experienced 
surgeons (300-500 previous LV) and two novices performed the operations as described 
earlier.13 The local ethics committee approved the study protocol (StV-Nr.16/2007) and all 
patients provided written informed consent. 
Laser beam power measurements were performed at baseline and after the application of 
every 25kJ throughout the LV procedure. For the measurements, a custom-built fibre holder 
was used to hold the fibre in a fixed position (figs. 1, 2). After positioning of the fibre, the 
laser was shortly activated at 120W output power. After its emission from the fibre, the laser 
beam had to be attenuated to allow a precise measurement with a short release time (figs. 1, 
3). Thus, the PM121 optical power meter (Thorlabs, Dachau, D) constantly measured 0.49% 
of the emitted power (fig. 1).  
For the analyses, the baseline value of each individual fibre was defined as 100%. Subsequent 
values in each measurement series were calculated and expressed as a percentage of this 
baseline value.  
To investigate if the clinical estimation of the fibres` performance was in line with the results 
of the measurements, the surgeons stated when a decrease of the vaporisation efficiency 
became apparent during the operation and estimated the overall decrease of power output in 
percent after the operation. The surgeons were blinded to the results of the performed 
measurements. After the procedure the fibre-tip was microscopically examined and the degree 
of degradation was classified to be mild (i.e. superficial whitening), moderate (i.e. superficial 
melting) or severe (i.e. deep melting or complete destruction of the fibre-tip).  
The impact of the surgeons’ experience on the performance of the fibres during the operation 
was analysed by comparing the course of power output between two groups of patients 
operated by experienced or inexperienced surgeons, respectively.   
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Power measurements during non-contact in-vitro vaporisation were performed to investigate 
the performance of two fibres up to 275kJ in a setting without any fibre-tissue contact as 
described earlier.13 
Two additional fibres with only a baseline and a terminal measurement before and after a 
regular 275kJ-LV were investigated to further define the impact of the measurement 
procedure itself on the course of power output,.  
Follow-up examinations were done 6 weeks and 6 months post-operatively. At each follow-
up visit, subjective (International Prostate Symptom Score and quality of life) and objective 
outcome parameters (maximum flow rate, residual volume and PSA-value) were recorded. 
Furthermore, patients were asked to report if bothering irritative voiding symptoms appeared.  
Statistical analysis was performed using the Predictive Analytics Software version 18 (SPSS 
Inc, Chicago, IL, USA). Continuous variables were compared using the Wilcoxon signed-
rank test. All p-values <0.05 were considered significant. 
 
Results  
Intra-operative results are summarised in table 2. A total of 24 procedures (68.6%) were 
completed using one fibre only. High prostate volume or early fibre degradation resulted in 
nine patients (25.7%) requiring the use of a second fibre and two patients (5.7%) requiring 
three fibres, of which only the first two were investigated in each case.  
By the end of the procedure, all fibres showed some degree of fibre degradation caused by 
melting and carbonisation at the emission window. These alterations slightly increased in 
parallel to the total amount of energy applied (fig. 4). Mild damage of the tip was found in the 
fibres from regular LV with less than 175kJ applied and from non-contact in-vitro 
vaporisation (figs. 4, 5). Moderate damage was found in fibres from LV with 175kJ or more 
applied (fig. 4). Severe damage resulted from extensive, unavoidable contact vaporisation 
(two fibres) or from exposure of the laser beam to prostate stones (one fibre; fig. 5). 
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The baseline values of the 46 fibres showed a certain inter-fibre variation (tab. 3). However, 
the course of power output was similar for all fibres. Typically, a steep decrease of power 
output within the first 25kJ was followed by a continuous mild decrease until the end of the 
procedure (fig. 6). After the application of 25kJ the median power output was 57.3% 
(interquartile range (IR): 50.2-69.6%) of the baseline value. This reduction of power output 
was statistically significant (tab. 3). The median power output at the end of the 275kJ-lifespan 
of the fibres was 48.8% (IR: 40.5-52.5%). None of the fibres had a stable course without any 
decrease of power output.  
The surgeons noted a decline of the vaporisation efficiency after the application of median 
100kJ (range 75-200kJ). The median estimated decrease of power output at the end of the 
operation was 60% (range 0-80%). 
The course of power output of the two fibres tested in-vitro without fibre-tissue contact was 
similar to the course of the fibres tested in-vivo but the decrease of power output was less 
extensive. The median power output was 65% of the initial value after the application of 50kJ 
and 58.9% after the application of 275kJ.  
The decrease of power output of the two controls with only a baseline and an endpoint 
measurement was no different than that of the 46 regular measurements (data not shown).  
The pre-operative prostate volume was not significantly different in the group of patients 
operated by experienced (group I) and inexperienced surgeons (group II). Although the lasing 
time was longer in group I, total operation time and applied total energy was significantly 
shorter (tab. 2). Median power output was slightly but significantly lower in group II after the 
application of 25 and 50kJ. Thereafter, power output was not significantly different anymore 
between the two groups (Fig. 7). 
The median duration of catheterization was 2 days (range: 1-13d) and the median post-
operative hospital stay 4 days (2-25d). Four patients needed re-catheterization due to 
hematuria (n=2) or urinary tract infection with high post-void residual volume (n=2). One 
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patient under oral anticoagulation needed transfusion due to persistent bleeding. Another 86-
year-old patient died five days post-operatively due to cardio-pulmonal de-compensation. 
After 6 weeks all investigated outcome parameters improved significantly and all patients 
were catheter-free (table 4).  Eleven patients (33%) reported irritative voiding symptoms. Two 
of those were diagnosed with a urinary tract infection. After 6 months all outcome parameters 
slightly improved further. Only three patients (11%) reported irritative voiding symptoms. 
One of those was diagnosed with a persisting obstructive adenoma and received a 
conventional transurethral resection 6 months post-operatively.  
 
Discussion 
The clinical observation of a decreasing ablative efficiency associated with structural changes 
at the laser beam emission window during 120W LBO-LV has been substantiated in the 
present investigation. Fibre degradation resulted in a significant loss of power output 
throughout the operation with a total drop in power output of more than 50%.  
Laser fibre deterioration and loss of power output have previously been reported for 
Nd:YAG- and KTP-laser treatment of the prostate.13,20-22 Heat at the tip of the fibre and 
insufficient heat resistance of the fibre itself are the main reasons for fibre degradation.3,17 
During KTP-LV heat accumulation at the fibre-tip is a result of adherent tissue debris and 
extensive fibre-tissue contact, which is difficult to avoid when performing LV with a 
recommended sweeping movement and an optimal fibre-tissue distance of only 0.5-1mm.23 A 
constant decrease of power output throughout the operation with a final loss of power output 
of 80% was measurable during 80W KTP-LV.13 Low power leads to a reduced ablative 
capacity, which in turn results in insufficient tissue ablation and increased tissue 
coagulation.16,17 The latter is a risk factor for irritative voiding symptoms,18,19 while 
insufficient tissue ablation may result in early prostatic re-obstruction and thus may 
compromise the long-term efficacy of the procedure. Re-treatment rates up to 50% within 4 
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years have been reported after KTP-LV.14 Bothersome post-operative voiding symptoms and 
high re-operation rates are well known problems after prostatic laser treatment and the main 
reasons preventing a breakthrough of several laser procedures in the past.24 
The novel features of the 120W HPS-laser were introduced to overcome the weaknesses of 
the KTP-laser. Higher power and an optimized laser beam profile, allowing for a more 
efficient tissue vaporisation and preventing early fibre degradation, have been reported.3 
Higher power together with an optimized laser beam collimation results in a higher power 
density and thus a stronger ablative capacity. The changes in beam characteristics additionally 
allow for efficient vaporisation at a greater distance from the tissue (1-3mm). This important 
innovation facilitates non-contact LV and consequently prevents fibre degradation and 
unwanted tissue coagulation.23  
The technical modifications markedly improved the performance of the system. The 120W 
HPS-laser has been shown to be 50% to 100% more efficient than the 80W KTP-laser in-
vitro.25-27 Fibre destruction and loss of power output observed in the present investigation are 
less vigorous than reported after KTP-LV.13 This illustrates that not only the ablative capacity 
but also the performance throughout the procedure significantly differs between the two 
lasers. The relatively constant course of power output on a medium level after the initial 
decrease allows for a more constant performance towards the end of the fibre’s lifespan 
compared to the KTP-laser and is the main reason for a recently released laser system 
upgrade. This upgrade extends the lifespan of a single fibre up to 400kJ in order to treat larger 
glands with a single fibre.  
The novel features facilitate non-contact LV and have a positive impact on the longevity of 
the fibre and the course of power output during the procedure. However, a significant problem 
of the greenlight laser procedure has not been solved by these innovations. Laser fibre 
degradation and loss of power output are still an issue during HPS-LV. The decrease of power 
output becomes clinically noticeable evidenced by the surgeons’ rating of the fibre 
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performance.  
The high power of the HPS system together with an inappropriate laser fibre seem to be the 
most important factor for the decrease of power output during HPS-LV. High power 
challenges the fibre material to a higher extent3 and might effect early alterations of the virgin 
fibres which, in turn, may cause the early steep decrease of power output observed in the 
present investigation.  
Fibre-tissue contact can more easily be prevented during LBO-LV than during KTP-LV and 
thus is only a minor reason for fibre degradation and loss of power output. The significant 
decrease of power output during non-contact in-vitro vaporisation also indicates that changes 
in power output occur largely independently from fibre-tissue contact. If fibre-tissue contact 
were an important reason for the decrease of power output, it would be more pronounced if 
inexperienced surgeons do a LV procedure as they more likely vaporize with tissue contact. 
However, in the present investigation, no major differences in the overall course of power 
output were detectable between the two groups of patients operated by experienced and 
inexperienced surgeons.  
If fibre-tissue contact is unavoidable under certain circumstances (e.g. a large median lobe or 
tight prostatic urethra), the distinct vulnerability of the HPS fibre becomes apparent. Three 
laser fibres were destroyed early during inevitable contact-vaporisation or exposure of the 
beam to prostate stones in the present investigation. The variances of the baseline power 
output values, the regularly seen satellite beams laterally to the main beam and an often 
observed imprecise alignment of the emission window and the positioning pin of the guiding 
knob are other factors pointing out that an upgrading in laser fibre quality is indicated. 
From the clinical point of view, the decrease of power output seems to be relevant as well. In 
the present investigation 33% of the patients reported irritative voiding symptoms and one 
patient needed re-operation due to persisting adenoma during a six months follow-up period. 
The typical side effects and need for re-operations have also been reported by others after 
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HPS-LV.28,29  
Most recently, the new 180W XPS laser system has been introduced. The HPS fibres can be 
used for the new system but only with 120W and not with 180W output power. Therefore, a 
novel fibre (MoXy™) with integrated water-cooling and a temperature-control sensor at the 
fibre-tip has been released. However, this fibre cannot be used for the 120W HPS-laser. It is 
desirable that the MoXyTM fibre meets the demands of XPS laser system and finally allows 
for a greenlight laser performance with a constantly high efficiency. 
Some limitations of the present investigation deserve mention. Due to inhomogeneities of the 
laser fibres (e.g. position of the emission window, alignment of the positioning pin) the 
standardised set-up with its fixed fibre position might have generated the inter-fibre variances 
of the baseline power outputs to some extent. However, the exact measurement of the course 
of power output of the single fibres was guaranteed by this fixation. Furthermore, the extent 
of the structural and functional changes might only be valid for the operative technique 
performed in this investigation. 
 
Conclusions: 
The technical refinements of the 120W HPS-laser have been implemented in order to improve 
the tissue ablative properties and the longevity of the laser fibre. However, fibre degradation 
and a significant decrease of power output are still detectable during HPS-LV. This is mainly 
due to the laser fibres, which are not fully appropriate for the high power delivery of the new 
system. Thus, there is still potential for further improvement of the laser’s performance. 
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Figure legends: 
Figure 1: Fibre holder and measurement setup: The middle and distal brackets of the holder 
(black arrowhead) fix the fibre (black arrow) using a snap fit. The laser beam, emitted from 
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the fibre-tip (white arrow) is refocused by a lens (f=25.4mm; small white arrowhead) and 
attenuated and redirected onto the detector (asterisk) by two 16 BPB 153 Fresnel beam 
samplers (Melles Griot, Bensheim, D; large white arrowhead) each of which reflects 
approximately 7% of the light, whereas 93% are transmitted. 
 
Figure 2: The laser fibre is placed in the large notch (black arrow) of the proximal bracket. 
The positioning pin (black arrowhead) of the guiding knob (asterisk) is stuck into the small 
notch (white arrow) to guarantee a steady longitudinal and rotational position of the laser 
beam for each measurement series. 
 
Figure 3: Schematic drawing of the measurement setup with the course of the green laser 
beam (BS = beam sampler). 
 
Figure 4: Fibre deterioration in the region of laser emission caused by melting and 
carbonisation. The alterations slightly increased together with the total energy applied. A 
virgin fibre can be seen on the left side, a fibre after 275kJ 80W KTP-LV on the right side. 
Scale bar: 2 mm. 
 
Figure 5: Impact of fibre-tissue contact: The laser fibre shows only slight degradation at the 
emission window following strict non-contact (NC) in-vitro vaporisation. Massive fibre 
deterioration however can be seen after vaporisation with unavoidable tissue contact (TC) due 
to a large median prostate lobe. Complete destruction of the fibre-tip can be seen after 
exposure of the laser beam to prostate stones (PS).  
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Figure 6: Median and interquartile range of all 46 measurement series. Following an early 
steep decrease, power output remained relatively constant on a medium level for the rest of 
the 275kJ fibre‘s lifespan. 
 
Figure 7: Courses of median power output of two groups of patients: group I operated by 
experienced and group II by inexperienced surgeons. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 







Table 1: Pre-operative parameters of 35 patients 
 
Number of patients 35 
Age (y) 70 (49-88) 
Prostate volume (ml) 55.2 (24.4-160.2) 
BPH 32 (91.4%) 
Prostate cancer 3 (8.6%) 
PSA (ng/ml) 3.47 (0.6-34.6) 
IPSS / QoL  17.5 (9-32) / 3 (1-6) 
Qmax (ml/sec) 9.0 (2.3-21.9) 
Residual volume (ml) 69 (0-360) 
Indwelling catheter 9 (26%) 
Anticoagulation (CD/PAI) 21 (60%) (3/18) 
Data are presented as median (range) or number (percent); BPH = benign prostatic 
hyperplasia, PSA = prostate-specific antigen, IPSS = International Prostate Symptom 
Score, Qol = quality of life, Qmax = maximum flow rate, CD = coumarin derivates, 
PAI = platelet aggregation inhibitors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Intra-operative parameters of the 35 patients in total and subdivided into two groups 
of patients operated by experienced or non-experienced surgeons.  
 
 Total 
Group I: 
experienced 
surgeons  
Group II:  
inexperienced 
surgeons  
Number of patients 35 24 (68.5%) 11 (31.5%) 
Number of fibres 46 31 (67.4%) 15 (31.6%) 
Operation time (min)* 90 (35-180) 80 (35-150) 100 (70-180) 
Lasing time (min) 39 (22-90) 42 (29-90) 38.5 (22-68) 
Applied energy per fibre (kJ) 215 (50-275) 217.5 (64-275) 215 (50-275) 
Applied energy per patient (kJ)* 270 (124-636) 238 (129-636) 273 (124-428) 
 
Data are presented as median (range) or number (percent). * Indicates a significant difference between the two groups 
 
T
 
able 3: Total number of fibres, median power output, and range after the application of n kJ 
Applied energy 
(kJ) 0 25 50 75 100 125 150 175 200 225 250 275 
Number of fibres 46 46 45 45 44 40 35 32 29 22 19 15 
Median power 
output (mW) 1 526 284 296 276 282 264 256 265 230 268 238 254 
Range of power 
output (mW) 1 328-674 141-511 65-471 128-419 103-446 100-396 63-399 93-408 82-490 78-437 79-429 80-363 
p-value  <0.001* <0.001* <0.001* <0.001* <0.001* <0.001* < .0010 * <0.001* <0.001* <0.001* <0.001* 
1  As measured by the power detector (0.49% of the fibre output power) 
* Indicates a significant decrease of the median power output compared to the baseline value (p < 0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
T
 
able 4: Postoperative outcome  
  6 weeks  6 months 
Number of patients  30   27  
IPSS / QoL  6 (1‐24) / 1 (0‐6)  4.5 (0‐22) / 1 (0‐5) 
Qmax (ml/sek)  20.3 (6.8‐40.4)  20.6 (9.4‐32.1) 
Residual volume (ml)  21.5 (0‐250)  13 (0‐171) 
PSA  (ng/ml)  2.53 (0.3‐28.1)  1.95 07)  (0.27‐9.
Indwelling catheter  0 (0%)  0 (0%) 
Irritative voiding symptoms 
       + UTI  2  0 
11 (33%)  3 (11%) 
Data are presented as median (range) or number (percent); IPSS = International Prostate Symptom Score, Qol = quality of life, 
max = maximum flow rate PSA = prostate‐specific antigen, UTI = urinary tract infection Q
 
 
